Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Total Current Liabilities (2020 - 2025)

Maxcyte (MXCT) has disclosed Total Current Liabilities for 6 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 9.56% to $14.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.3 million through Dec 2025, down 9.56% year-over-year, with the annual reading at $14.3 million for FY2025, 9.56% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $14.3 million at Maxcyte, down from $16.1 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $18.1 million in Q2 2022, with the low at $11.6 million in Q2 2025.
  • Average Total Current Liabilities over 5 years is $15.0 million, with a median of $15.5 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities surged 44.46% in 2022, then dropped 27.08% in 2023.
  • Over 5 years, Total Current Liabilities stood at $15.6 million in 2021, then decreased by 1.22% to $15.4 million in 2022, then increased by 15.74% to $17.9 million in 2023, then dropped by 11.65% to $15.8 million in 2024, then decreased by 9.56% to $14.3 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $14.3 million, $16.1 million, and $11.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.